Deuremidevir Hydrobromide Tablets

Effects and efficacy:
For the treatment of mild to moderate novel coronavirus pneumonia (COVID-19) in adults with high risk factors for progression to severe illness. If accompanied by at least one of the following diseases or conditions, it is considered to be a high risk factor for progression to severe COVID-19: cardiovascular disease (including congenital heart disease) or hypertension; chronic lung disease (such as chronic obstructive pulmonary disease [COPD] asthma [moderate to severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension); diabetes; immunosuppressive disease or receiving immunosuppressive treatment (such as long-term use of corticosteroids or other immunosuppressive drugs leading to decreased immune function); obesity or overweight (body mass index [BMI] > 25kg/m); sickle cell disease; active cancer; age ≥ 60 years; The use of this product is not limited to the above medical conditions or factors, other medical conditions or factors may also put individual patients at high risk of progression to severe COVID-19, and doctors should weigh the benefits and risks of individual patients before prescribing.
Dosage and administration:
It is recommended to take orally 10 times in a row, once every 12 hours, for a total of 5 days. Day 1: 600 mg (6 tablets) each time, orally once every 12 hours, for 2 times; Days 2 to 5: 300 mg (3 tablets) each time, orally once every 12 hours, for 8 consecutive times. This product should be taken as soon as possible after COVID-19 is confirmed. This product can be taken on an empty stomach or after a normal meal.
Drug contraindications:
Allergic to this product is prohibited. It is prohibited during pregnancy and lactation. It should be used with caution in patients with liver and kidney dysfunction
Related dosage forms:
Tablets